|
|
|
|
Intravitreal Bevacizumab Can Stabilise Vision in Patients With Degenerative Eye Diseases: Presented at COS
-- Bevacizumab is effective in treating several ophthalmological conditions that can threaten visual acuity, according to a study presented here at the 72nd Annual Meeting and Exhibition of the Canadian Ophthalmological Society (COS).
|
|
|
Intravitreal bevacizumab for idiopathic choroidal neovascularization
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Journal of American Association for Pediatric Ophthalmology and Strabismus , 06/29/09 Print Save in My Library Free Abstract Cakir M et al.- An otherwise...
|
|
|
Intravitreal Bevacizumab Can Stabilise Vision in Patients With Degenerative Eye Diseases: Presented at COS
-- Bevacizumab is effective in treating several ophthalmological conditions that can threaten visual acuity, according to a study presented here at the 72nd Annual Meeting and Exhibition of the Canadian Ophthalmological Society (COS).
|
|
|
Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynam
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Acta Ophthalmologica, 06/29/09 Print Save in My Library Free Abstract Byeon SH et al.- Pulsating PCV showed distinctive features including a relatively...
|
|
|
OXiGENE Initiates Phase-II Trial Of Zybrestat
Zybrestat to treat Ophthalmology in patients with PCV OXiGENE has initiated the phase-II study of vascular disrupting agent drug candidate, Zybrestat for ophthalmology in patients with polypoidal choroidal vasculopathy (PCV).The...
|
|
|
New micro-shunt device facilitates aqueous outflow
Physiologic aqueous outflow pathways include the conventional outflow pathway and the uveoscleral outflow.Whereas surgical procedures such as canaloplasty and trabecular bypass stents aim to enhance conventional outflow, new devices such...
|
|
|
OXiGENE initiates trial of intravenous fosbretabulin for treating polypoidal choroidal vasculopathy
SOUTH SAN FRANCISCO, Calif.OXiGENE has initiated a phase 2 study of its vascular-disrupting agent fosbretabulin for treating patients with polypoidal choroidal vasculopathy, the company announced in a press release. Expected to...
|
|
|
Combined PDT-intravitreal bevacizumab reduces pigment epithelial detachment
Photodynamic therapy and adjunctive intravitreal bevacizumab minimized pigment epithelial detachment associated with age-related macular degeneration, a study showed.'Combined PDT and intravitreal bevacizumab may decrease the [pigment...
|
|
|
CCR3 linked to neovascular AMD, according to researchers
Lexington, KYResearchers identified a biological marker, CCR3, which is linked to the development and progression of neovascular age-related macular degeneration (AMD).The CCR3 marker also plays a role in the inflammation process and was...
|
|
|
RADICAL study shows positive 12-month results
Ophthalmology Times E-News Vancouver, British ColumbiaQLT Inc.has announced positive 12-month primary analysis results from a phase II study in patients with wet age-related macular degeneration (AMD), known as RADICAL (or Reduced fluence...
|
|
|
Study describes long-term effects of PDT in wet AMD
Submit a Comment Photodynamic therapyis safe for long-term treatment of exudative age-related macular degeneration, but it is not definitive because it does not stop lesion growth.In 262 patients treated with PDT for wet AMD who were...
|
|
|
Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patien
1Department of Ophthalmology, University Hospital of Grenoble, Joseph Fourier University, Grenoble, France 2HES-SO Valais, Sion, Switzerland 3HP2 Laboratory, EA 3745 INSERM ERI 0017, Joseph Fourier University, Grenoble, France Correspondence...
|
|
|
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne c
VANCOUVER, June 15 /PRNewswire-FirstCall/ -- QLT Inc.(NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th...
|
|
|
Most patients want cancer prognosis test
-0400 (Reuters Health) By Amy Norton NEW YORK (Reuters Health) - Most patients with a form of eye cancer called choroidal melanoma want to undergo a genetic test that can predict their likely outcome, a small study suggests.Moreover...
|
|
|
QLT announces 12-month results from phase 2 study of combination therapy
VANCOUVER, British Columbia QLT has announced 12-month primary results from the European arm of the Novartis-sponsored SUMMIT clinical program.The randomized, double-masked, multicenter, phase 2 MONT BLANC study is evaluating the efficacy...
|
|
|
Biotechnology breakthrough against AMD
A team of researchers led by Dr.Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. The marker, a...
|
|
|
QLT Announces 12-month Results From Novartis Sponsored MONT BLANC Study Evaluating Standard-fluence Visudyne(R
QLT Inc.(NASDAQ: QLTI; TSX: QLT) announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology...
|
|
|
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R
VANCOUVER, June 15 (HSMN NewsFeed) - QLT Inc.(NASDAQ: QLTI ; TSX: QLT ) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th...
|
|
|
Major Breakthrough In Macular Degeneration
A team of researchers led by Dr.Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. The marker, a...
|
|
|
::: QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudy
VANCOUVER, June 15 /PRNewswire-FirstCall/ -- QLT Inc.(NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th...
|
|
|
QLT Inc. (QLTI) Announces 12-month Results from Novartis Corporation (NVS) Sponsored MONT BLANC Study Evaluati
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc.today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European...
|
|
|
Major breakthrough in early detection and prevention of AMD
A team of researchers led by Dr.Jayakrishna Ambati at the has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. The marker, a receptor known as CCR3,...
|
|
|
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R
/PRNewswire-FirstCall via COMTEX/ -- QLTI | Quote | Chart | News | PowerRating -- QLT Inc.(NASDAQ: QLTI; TSX: QLT | Quote | Chart | News | PowerRating) today announced that twelve-month primary analysis results from the Novartis sponsored...
|
|
|
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc.(NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th...
|
|
|
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc.(NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th...
|
